Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Hungary Bill notified to include cannabinoids on narcotics list ...
  • Panama Bill regulating hemp approved in first debate ...
  • Germany First cannabis club in Lower Saxony harvests 200 plants ...
  • Belgium List of notified herbal products for smoking updated ...
  • Lithuania Seimas approves amendments to Fibre Hemp Law ...
  • Uruguay More potent cannabis variant sold in pharmacies from today ...
  • Italy EC assessing compliance of bill restricting hemp to industrial uses ...
  • Europe Council adopts new CLP regulation ...
  • France No plans proposed to extend medical cannabis experiment ...
  • California - United States Court rejects industry attempt to block new hemp regulation ...
  • Germany Majority of survey respondents think cannabis legalisation was wrong ...
  • World International E-waste Day raises awareness of e-waste ...
View all
News analysis

A ‘milestone’ for psychedelics as clinical trial begins in US with FDA’s blessing

Written by || 18th July 2022 || News analysis | Psychedelics | GeographiesNorth America United States

As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances.

The first Phase 1 study into psilocin and psilocybin to be approved by the US Food and Drug Administration (FDA) will examine the physiological and psychological effects of the mushroom-derived compounds when delivered orally and sublingually to healthy adults.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the ECigIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.